InflaRx N.V.
IFRX
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio centers on proprietary antibody and small-molecule programs designed to address autoimmune and other inflammatory diseases through precise modulation of immune signaling. Its current pipeline includes vilobelimab, an intravenously administered anti-C5a antibody, and an oral C5aR inhibitor in development for inflammatory indications. InflaRx serves the biotechnology and healthcare sectors, with research and operational activities in Germany and the United States. The company’s work is centered on advancing novel treatments for severe inflammatory conditions where targeted complement inhibition may play an important therapeutic role.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
-€10K
▼ -82.3% YoY
Net Income (TTM)
-€39M
▲ +0.9% YoY
Op. Margin
361793.12%
▼ -132551.8pp YoY
ROIC
-72.84%
▼ -22.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€24M
▲ +27.1% YoY
Op. Cash Flow (TTM)
-€24M
▲ +27.3% YoY
Net Debt
-€46M
Net Cash Position
Cash & Equiv.
€46M
Continue Research
Peers
Biotechnology · Pick stocks to compare with IFRX
InflaRx (IFRX) in three numbers
Questions about InflaRx
Is InflaRx a high-quality business?
InflaRx scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$46M, and its weakest is return on capital at -72.8%. The Quality tab shows every check against its target.
Does InflaRx (IFRX) pay a dividend?
No. InflaRx (IFRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IFRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.